David Colin Conway Llewellyn

ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

BioMotiv LLC operates as a research institution in the field of therapeutics. It focuses in disease areas and classes of therapeutics such as small molecules, antibodies, proteins, and nucleotides. The company was founded on September 10, 2012 and is headquartered in Cleveland, OH.

ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.

Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.

Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Stevenage Bioscience Catalyst offers access to equipment and facilities that would otherwise be beyond the reach of small or medium-sized companies. The company is headquartered in Stevenage, the United Kingdom.

The Danish Cancer Society provides support and resources for those affected by cancer, including patients and their families. The non-profit company is based in Copenhagen, Denmark and has subsidiaries in Denmark. The Danish company offers the latest information on patient involvement in cancer treatment and tools for utilizing patient-reported information. The organization also promotes cancer prevention through screening and works towards reducing the number of cancer cases and improving the quality of life for those who have survived cancer.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.

Ducentis Biotherapeutics Ltd. develops novel therapies for inflammation and autoimmune disease. The company was founded by Rebecca Ashfield, David Blackbourn and Philip Huxley in March 2015 and is headquartered in Witney, the United Kingdom.

CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany.

Avvinity Therapeutics Ltd. develops novel immuno-therapeutics. The British company was founded in 2016 by Mike Westby, Jonathan David Moore. The CEO is Nick Staples.

NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom.

Scioto Biosciences, Inc. operates as a preclinical stage company. It develops therapies to transform the delivery of microbiome therapeutics. The firm?s platform enhances probiotics that are used for diabetes, neurological disorders, gastrointestinal health and alternatives to in-feed antibiotics. The company was founded by Joseph P. Trebley, Jim Schulz, Goodman Steve, Lauren O. Bakaletz, Michael Bailey and Gail E. Besner in May 2017 and is headquartered in Indianapolis, IN.

ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021.

AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

Synklino ApS is a Danish biotech company that focuses on developing innovative therapies against virus infections. The company's first-in-class drug candidate, Syn002, targets cytomegalovirus infection in transplantation patients and aims to change the current antiviral treatment paradigm. Synklino is owned by renowned Nordic funds and institutional investors, including Eir Ventures, the Danish Growth Fund, and PKA, as well as approximately 70 private shareholders. The company is a spinout from the University of Copenhagen and the Technical University of Denmark and is incubated at the BioInnovation Institute in its prestigious Creation House program.

HatchBox Bioconsulting LLC provides life science advisory services.

Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom.

Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge.

RQ Biotechnology Ltd. is a British company that provides biotechnology research and development services. The company was founded in 2021 by Michael Westby, Jane Osbourn, Paul Kellam. Hugo Rupert Alexander Fry has been the CEO of the company since 2022.

BioNeex, Inc. is an American company located in Syracuse, NY, that operates as a drug development platform. It was founded by Smbat Rafayelyan and Tigran Rafayelyan. Smbat Rafayelyan has been the CEO since 2018. The company says this about itself: BioNeex is the first R&D open exchange platform in the biopharma industry, facilitating licensing and co-development partnerships for preclinical and clinical-stage drug candidates between biotech, biopharma companies and research institutions. Data posted on the drug candidate marketplace is listed by biotech, biopharma companies, and research institutions, enabling potential licensing and co-development partners as well as investors to contact them directly with one click.

Lifearc Ventures (Lifearc Ventures) is a venture capital firm, a subsidiary of Lifearc. The firm is headquartered in London, United Kingdom.

Vantage Biosciences Ltd. develops drugs for diabetic eye disease. The British company was founded by Andre Badalyan, Katie Sunnucks, Graeme R. Martin, Alek Safarian.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.